That’s very different from the results that Paxlovid’s maker, Pfizer, first reported in 2022. In that study, Pfizer found that the drug reduced hospitalizations and deaths from COVID-19 by 89% ...

Prescribing guidelines and the benefits and risks of nirmatrelvir/ritonavir for COVID patients ...

Cambia has possible interactions with alcohol, some other drugs, and certain supplements. Examples include other nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen. Talk with your ...

As COVID-19 cases rise once again and the federal government gears up to increase distribution of Paxlovid, we thought we’d take this opportunity to review information about the drug and share ...

The treatment, a combination of the drugs nirmatrelvir and ritonavir, was fully approved by the FDA in May 2023. Early evidence showed that Paxlovid reduced the risk for severe disease ...

The assessment of causation for a potential drug interaction requires thoughtful consideration of the properties of both the object and precipitant drugs, patient-specific factors, and the ...

Follow-up rates were similar in the treated and untreated groups, with slightly more adverse events demonstrated in the Paxlovid vs control group. Researchers conducted a retrospective electronic ...

Pfizer reckons it will make a whopping $22 billion in sales of its oral COVID-19 antiviral Paxlovid in 2022 ... anti-clot drug Eliquis (apixaban) and Vyndaqel/Vyndamax (tafamidis meglumine ...

Paxlovid does not significantly reduce COVID-19 hospitalization and mortality among vaccinated older adults, according to new UCLA-led research. The health care sector is increasingly turning to ...

In jails and prisons, drugs are still available, effective treatment is rare, and overdoses occur. People can also cycle in and out of jail, ending up back on the street without meaningful care or ...

Mexican authorities have been waging a deadly battle against drug cartels for nearly two decades, but with limited success. Thousands of Mexicans—including politicians, students, and journalists ...

Despite advancements in vaccination and treatment, COVID-19 was responsible for 1.8% of all deaths in the United States during the week of January 4-11, 2025. 1-3 The virus disproportionately affects ...